Explore

Trendline Trendline
Lifordi Immunotherapeutics Reveals Phase 1 Data for LFD-200 at EULAR 2026, Indicating Promising Rheumatoid Arthritis Treatment

Lifordi Immunotherapeutics Reveals Phase 1 Data for LFD-200 at EULAR 2026, Indicating Promising Rheumatoid Arthritis Treatment

Lifordi Immunotherapeutics Reveals Phase 1 Data for LFD-200 at EULAR 2026, Indicating Promising Rheumatoid Arthritis Treatment
Trendline Trendline
Lifordi Immunotherapeutics Presents Promising Phase 1 Data for Rheumatoid Arthritis Treatment

Lifordi Immunotherapeutics Presents Promising Phase 1 Data for Rheumatoid Arthritis Treatment

Lifordi Immunotherapeutics Presents Promising Phase 1 Data for Rheumatoid Arthritis Treatment
Trendline Trendline
Corsair Pharma Presents Phase 1 Data for TRX-248 Transdermal System at Pulmonary Hypertension Conference

Corsair Pharma Presents Phase 1 Data for TRX-248 Transdermal System at Pulmonary Hypertension Conference

Corsair Pharma Presents Phase 1 Data for TRX-248 Transdermal System at Pulmonary Hypertension Conference
Trendline Trendline
Kali Therapeutics to Present KT209 Trispecific Antibody at EHA 2026 Congress

Kali Therapeutics to Present KT209 Trispecific Antibody at EHA 2026 Congress

Kali Therapeutics to Present KT209 Trispecific Antibody at EHA 2026 Congress
Trendline Trendline
Lifordi Immunotherapeutics Presents Phase 1 Data for LFD-200 at EULAR 2026

Lifordi Immunotherapeutics Presents Phase 1 Data for LFD-200 at EULAR 2026

Lifordi Immunotherapeutics Presents Phase 1 Data for LFD-200 at EULAR 2026
Trendline Trendline
Verdiva Bio Unveils Promising Preclinical Data on Obesity Drug Candidates at ADA Scientific Sessions

Verdiva Bio Unveils Promising Preclinical Data on Obesity Drug Candidates at ADA Scientific Sessions

Verdiva Bio Unveils Promising Preclinical Data on Obesity Drug Candidates at ADA Scientific Sessions
Trendline Trendline
Seaport Therapeutics Advances GlyphAgo with Positive Phase 1 Trial Results for Anxiety Treatment

Seaport Therapeutics Advances GlyphAgo with Positive Phase 1 Trial Results for Anxiety Treatment

Seaport Therapeutics Advances GlyphAgo with Positive Phase 1 Trial Results for Anxiety Treatment
Trendline Trendline
Lifordi Immunotherapeutics Unveils Promising Phase 1 Data for Rheumatoid Arthritis Treatment

Lifordi Immunotherapeutics Unveils Promising Phase 1 Data for Rheumatoid Arthritis Treatment

Lifordi Immunotherapeutics Unveils Promising Phase 1 Data for Rheumatoid Arthritis Treatment
Trendline Trendline
Protego Biopharma Appoints Jae B. Kim as Chief Medical Officer to Advance Drug Development

Protego Biopharma Appoints Jae B. Kim as Chief Medical Officer to Advance Drug Development

Protego Biopharma Appoints Jae B. Kim as Chief Medical Officer to Advance Drug Development
Trendline Trendline
Merck and Gilead Discontinue Phase 3 Study of Trodelvy and KEYTRUDA Combination

Merck and Gilead Discontinue Phase 3 Study of Trodelvy and KEYTRUDA Combination

Merck and Gilead Discontinue Phase 3 Study of Trodelvy and KEYTRUDA Combination
Trendline Trendline
Coya Therapeutics Initiates Blinded Extension Phase in ALS Clinical Trial

Coya Therapeutics Initiates Blinded Extension Phase in ALS Clinical Trial

Coya Therapeutics Initiates Blinded Extension Phase in ALS Clinical Trial
Trendline Trendline
Antengene Unveils Preclinical Data on ATG-207 for Autoimmune Disease Treatment

Antengene Unveils Preclinical Data on ATG-207 for Autoimmune Disease Treatment

Antengene Unveils Preclinical Data on ATG-207 for Autoimmune Disease Treatment